

Rapid BRCA protocol

Affected with breast or ovarian cancer and genetic test result will affect surgical or medical treatment *

*Genetic test result will result in a change in chemotherapy from standard protocol or result in different surgical decision

Box A.

- Breast cancer under 30 years
- Triple negative breast cancer under 60 years
- Bilateral breast cancer under 50 years
- Breast cancer under 45 years and another relative** also affected under 45 years
- Breast cancer and ovarian cancer any age
- Non-mucinous ovarian cancer any age

**sister/mother/grandmother/aunt on maternal or paternal side

Patient meets criteria for rapid genetic testing

1. Take blood sample **and consent for test of breast or ovarian cancer predisposition genes (BRCA1, BRCA2, CHEK2 and PALB2 will be offered to breast cancer patients fulfilling above criteria. In addition TP53 will be offered to those diagnosed under 30 years. BRCA1 and BRCA2 will be offered to ovarian cancer patients)**
2. Complete Rapid BRCA referral and blood form
3. Email cancergenetics.stg@nhs.net
4. Patient will be contacted by Genetics team within two working days for consultation
5. BRCA result will be available within four weeks of blood sample being received in the Genetics lab

Box B. Does not meet Box A criteria, but at least two relatives affected with breast cancer or one relative with male breast cancer or ovarian cancer

Patient meets criteria for rapid assessment
Please make patient aware that referral is for an assessment and testing may not be offered

1. Complete Rapid BRCA referral form
2. Blood sample can be taken for storage
3. Email cancergenetics.stg@nhs.net Patient will be contacted by Genetics team within two working days for consultation **to assess if eligible for BRCA test**
4. If Genetics team determine patient eligible for test, BRCA result will be available within four weeks of blood sample being received in Genetics lab (if sample was sent for storage)

For feeding RAPID BRCA test results back to the breast unit for all St George's patients.

The clinician receiving the result needs to email the breast MDT coordinator immediately:

stgh-tr.breast-mdt@nhs.net

with one of the two following sentences:

This patient has a clinically actionable pathogenic BRCA1/ BRCA2 variant (delete as appropriate)

This patient does **NOT** have a clinically actionable pathogenic BRCA1 or BRCA2 variant